EVERSANA announced on August 26 that it entered into an agreement with Waltz Health to merge into one company.
Waltz Health is a digital health company that develops technologies and services to support better-informed decisions on prescription care. Designed for payers, pharmacies, pharmacy benefit managers and self-insured employers, the company offers AI-driven marketplaces to lower overall drug costs. This provides better pricing options and more information for consumers while also helping payers take control of their pharmacy benefits.
EVERSANA provides a fully integrated and independent commercial services platform designed to address global pricing, access, reimbursement, adherence and product delivery challenges in the life sciences sector. It is a portfolio company of private equity group Water Street.
Sidley Austin advised Waltz throughout the transaction.
The merger integrates Waltz Health’s software-powered drug-price marketplaces and direct-to-payer model into EVERSANA’s global commercialization services, creating a next-generation approach for drug access and value in the U.S. healthcare system. The merger will be especially impactful for lowering the cost of specialty medications and high-cost drug classes like GLP-1s.
According to data captured in the LevinPro HC database, this deal represents the second pharmacy benefits manager (PBM) transaction of the year. There were no PBM transactions reported in 2024 or 2023.
